As part of a clinical trial, a neurologist conducted brain scans to study the effects of psilocybin, the main psychoactive component of magic mushrooms. The trial participants were unsure if they were given psilocybin or a placebo, but the neurologist experienced psychedelic effects during the scan. The study found that psilocybin disrupts the brain’s typical pathways and forms new connections. This may explain why psychedelics show promise in treating mental health disorders. Psilocybin has been designated a breakthrough medicine by the FDA. Despite the small scale of the study, it provides insights into the potential therapeutic effects of psilocybin.
